Zhongyuan Concord is a unique biomedical stock with the most potential and long-term investment value. The unique monopoly of stem cells and the great potential of medical effect are incomparable and irreplaceable, and the future glory is inevitable. At present, it is a piece of buried gold, which is just a good time to collect. The stock price may break through 1 yuan in 22-222! Buying this stock requires great patience and confidence, and it is recommended to buy it with 1/1 of the funds.

after full communication with the management of the company, institutions are generally optimistic about the future growth potential of the company. Li Defu, Chairman of the Company, Dr. Wu Mingyuan, General Manager, Dr. Li Tongen, who is in charge of gene business, and Wan Fang, Marketing Director of Concord Stem Cell Company, etc. attended the institutional exchange activities. General Manager Wu Mingyuan introduced the current global development of stem cell industry. In the past year, the company's business line management has become increasingly clear: in storage-intensive cultivation; Accurate positioning and rational layout of products in the field of genetics; Beauty products and lead the trend in the field of cosmetics; Take advantage of the situation and make breakthroughs as soon as possible in the declaration of stem cell preparations and new drugs. At the same time, Zhongyuan Concord also announced the establishment of a merger and acquisition fund to integrate external resources and realize the company's extended growth. In the future, Zhongyuan Concord will focus on establishing a GMP workshop network for cell preparation in five regions: Northeast China, Central China, East China, South China and Northwest China. At the same time, the company will build two industrialization bases of cell and gene life science and technology, including the south and the north.